NCT04779008 Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG
| NCT ID | NCT04779008 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Henan Institute of Cardiovascular Epidemiology |
| Condition | Coronary Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2021-03-10 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 210 participants in total. It began in 2021-03-10 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Remote Ischemic preconditioning (RIPC) has been reported to improve myocardial microcirculation, promote collateral circulation recruitment, and improve myocardial perfusion in patients.Two large randomized controlled trials demonstrated a perioperative cardioprotective effect of RIPC (reduced troponin levels), but did not find that a single preoperative RIPC improved long-term outcomes of coronary artery bypass grafting(CABG).The effect of a single RIPC before CABG may be too short. This study aims to investigate whether long-term RIPC improved myocardial perfusion in patients 3 months and 6 months after CABG surgery , and to detect changes in blood vascular endothelial growth factor, Nitrc Oxide, adenosine，and Endothelin-1, and to observe MACCE event rates at 12 months.
Eligibility Criteria
Inclusion Criteria: * Three coronary artery lesions, CABG surgery was planned Exclusion Criteria: * The patients could not tolerate ripc; * peripheral vascular disease affecting upper limbs * Acute myocardial infarction complicated with cardiogenic shock，in recent 30 days, * Emergency cases * Severe structural heart disease and severe arrhythmia ； * The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively; * Severe liver, renal and pulmonary disease * Mental disorder can't cooperate; * Inability to give informed consent； * Patients on glibenclamide or nicorandil, as these medications may interfere with RIC * pregnant;
Contact & Investigator
Muwei Li, Ph.D
PRINCIPAL INVESTIGATOR
Fuwai central China cardiovascular hospotial
Frequently Asked Questions
Who can join the NCT04779008 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Coronary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04779008 currently recruiting?
Yes, NCT04779008 is actively recruiting participants. Contact the research team at xinyiguoquan@163.com for enrollment information.
Where is the NCT04779008 trial being conducted?
This trial is being conducted at Zhengzhou, China.
Who is sponsoring the NCT04779008 clinical trial?
NCT04779008 is sponsored by Henan Institute of Cardiovascular Epidemiology. The principal investigator is Muwei Li, Ph.D at Fuwai central China cardiovascular hospotial. The trial plans to enroll 210 participants.